Fulltext

The EU-project ERAPharm - Incentives for the further development of guidance documents? (4 pages)

Knacker, Thomas ; Duis, Karen ; Ternes, Thomas ; Fenner, Kathrin ; Escher, Beate ; Schmitt, Heike ; Römbke, Jörg ; Garric, Jeanne ; Hutchinson, Thomas ; Boxall, Alistair

In: Environmental Science and Pollution Research, 2005, vol. 12, no. 2, p. 62-65

Ajouter à la liste personnelle
    Titre
    • The EU-project ERAPharm - Incentives for the further development of guidance documents? (4 pages)
    Auteur
    • Knacker, Thomas. Dr. Thomas Knacker ECT Oekotoxikologie GmbH Böttgerstr. 2-14 D-65439 Flörsheim Germany
    • Duis, Karen. Karen Duis ECT Oekotoxikologie GmbH Böttgerstr. 2-14 D-65439 Flörsheim/Main Germany
    • Ternes, Thomas. PD Dr. habil. Thomas A. Ternes ESWE-Institut für Wasserforschung und Wassertechnologie GmbH Kurfürstenstr. 6 D-65203 Wiesbaden
    • Fenner, Kathrin. Kathrin Fenner Eidgenössische Anstalt für Wasserversorgung, Abwasserreinigung und Gewässerschutz (EAWAG) Ueberlandstrasse 133 8600 Duebendorf SCHWEIZ
    • Escher, Beate. Beate Escher, Swiss Federal Institute for Environmental Science and Technology (EAWAG) and Department of Environmental Sciences, Swiss Federal Institute of Technology Zürich, CH-8600 Dübendorf, Switzerland
    • Schmitt, Heike. Heike Schmitt RIVM – LER Postbox 1 3720 BA Bilthoven THE NETHERLANDS
    • Römbke, Jörg. Dr. Jörg Römbke ECT Ökotoxikologie GmbH Böttgerstraße 2-14 D-65439 Flörsheim Germany
    • Garric, Jeanne. Dr. Jeanne Garric Centre National du Machinisme Agricole du Genie rural des Eaux et des Forets (Cemagref) Laboratorie d'écotoxicologie 3 bis quai Chauveau, CP 220 69336 LYON, Cedex 9 FRANCE
    • Hutchinson, Thomas. Thomas Hutchinson AstraZeneca R&D Global Safety Assessment S-151 85 Södertälje SWEDEN
    • Boxall, Alistair. Alistair B.A. Boxall Central Science Laboratory Sand Hutton York YO41 1LZ UNITED KINGDOM
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • Environmental Science and Pollution Research, 2005, vol. 12, no. 2, p. 62-65. Ecomed
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:319136
    Summary
    -: Triggered by the detection of a large variety of pharmaceuticals in surface waters, soils and groundwaters across the world (e.g. Halling- Sørensen et al. 1998, Daughton & Ternes 1999, Jones et al. 2001, Heberer 2002) and the widespread occurrence of endocrine active compounds and related effects in the environment (e.g. Purdom et al. 1994, Tyler et al. 1998, Vethaak et al. 2002), pharmaceuticals in the environment have become an issue for both the scientific and the public community. During the last few years, our understanding of the fate and effects of pharmaceuticals in the environment has progressed significantly. However, there are still a number of uncertainties concerning the effects of pharmaceuticals on the environment and the assessment of potential exposure (e.g. Hanisch et al. 2004, Salomon 2005). These uncertainties will be addressed by the EU-project ‘Environmental risk assessment of pharmaceuticals' (ERAPharm). This project, a specific targeted research project, is carried out within the priority ‘Global change and ecosystems' of the 6th framework programme of the European Union. ERAPharm has started on 1st October 2004; the project duration is three years